Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Share-based Compensation (2016 - 2025)

Anaptysbio's Share-based Compensation history spans 10 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 3.93% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $36.1 million, up 5.94%, while the annual FY2025 figure was $36.1 million, 5.94% up from the prior year.
  • Share-based Compensation reached $8.5 million in Q4 2025 per ANAB's latest filing, down from $9.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.1 million in Q1 2024 to a low of $2.9 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $6.4 million, with a median of $7.6 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: plummeted 31.26% in 2022, then skyrocketed 172.97% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $4.0 million in 2021, then skyrocketed by 68.05% to $6.7 million in 2022, then grew by 21.33% to $8.1 million in 2023, then rose by 0.9% to $8.2 million in 2024, then grew by 3.93% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Share-based Compensation are $8.5 million (Q4 2025), $9.2 million (Q3 2025), and $9.2 million (Q2 2025).